Clinical-stage biotech Whitehawk Therapeutics (Nasdaq:WHWK) rose 25.77% on 13 May 2026 amid an extraordinary surge in trading activity, with reported Volume of 5.27 million shares running at 39.27 times the stock's usual pace.

Key Highlights

  • WHWK closed the screener at USD 4.93, up 25.77% on the session.
  • Volume of 5.27 million shares ran at 39.27× normal activity — one of the day's most extreme readings.
  • Market Capitalisation was reported at approximately USD 243.8 million.
  • Trailing twelve-month diluted EPS stood at -USD 1.67.
  • Clinical-stage biotechs remain exposed to binary trial events and Capital-raising dynamics.

What Happened

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) was a standout volume name on Top Gaining US Stocks screener for 13 May 2026. The screener recorded a single-session change of 25.77% to USD 4.93, with reported volume of 5.27 million shares — an extraordinary 39.27 times the stock's typical activity.

Such an extreme relative-volume reading is uncommon, particularly for a clinical-stage biotech. It typically reflects a sudden burst of attention from both retail and institutional participants, often connected to perceived clinical or financial catalysts that may not yet be fully visible to all Market Participants.

With a market capitalisation of approximately USD 243.8 million, WHWK sits in the small-cap biotech segment, where investor base shifts and clinical updates can produce pronounced single-session moves.

Market Context

Sentiment toward US-listed clinical-stage biotechs has continued to be volatile through 2025 and into 2026. Capital availability, interest-rate expectations, and the pace of clinical readouts all play significant roles in shaping the sector's overall behaviour.

On 13 May 2026, WHWK's move took place alongside several other healthcare-adjacent names — including SELLAS Life Sciences (SLS) and Replimune Group (REPL) — suggesting that biotech-related sentiment was a meaningful Factor in the day's risk-on tone.

Within the biotech complex, relative-volume readings approaching 40× are particularly noteworthy. They typically indicate that a stock has moved from being a relatively quiet listing to the centre of speculative or institutional attention. Such transitions can sometimes precede sustained rallies but can equally be followed by sharp retracements.

Structurally, small-cap biotechs remain reliant on Capital Markets to fund ongoing Research and Development. Periods of supportive financing conditions tend to lift the entire complex, while episodes of tighter financing can produce broad-based de-ratings.

Company Overview

Whitehawk Therapeutics, Inc. is a US-listed clinical-stage biotechnology company tracked by under the ticker WHWK. The screener does not provide a detailed description of the company's clinical programs, and this article does not extrapolate beyond what is visible.

As of the 13 May 2026 screener snapshot, WHWK had a market capitalisation of approximately USD 243.8 million. The trailing twelve-month diluted EPS figure of -USD 1.67 reflects the cash-intensive Economics typical of clinical-stage biotechs.

From a market-behaviour standpoint, WHWK fits the pattern of small-cap clinical-stage biotechs capable of producing extreme single-session moves on sector sentiment and on any company-specific catalysts that may emerge.

Screener Data

WHWK's relative volume reading of 39.27 is one of the most extreme on the day's screener. For a small-cap biotech with a market capitalisation around USD 244 million, this level of participation indicates a meaningful shift in the stock's investor base or attention profile.

The combination of a 25.77% price gain and such elevated relative volume implies that, despite the surge in attention, the upside was constrained by significant two-way flow. That can sometimes indicate that institutional and retail participants are taking different views on the move, with attendant implications for follow-on Volatility.

The trailing diluted EPS of -USD 1.67 is consistent with clinical-stage biotech economics. Investors should examine cash position, runway, and pipeline progression directly to interpret the figure within the broader operating context.

Risks to Watch

Clinical trial risk

Clinical-stage biotechs face binary outcomes at major trial readouts. Adverse safety or efficacy results can drive significant declines, while favourable readouts can produce comparable rallies.

Volume-driven Reversal risk

Stocks with relative-volume readings approaching 40× their norm are prone to volatile follow-on sessions. The flows that drive a one-day surge can reverse rapidly if attention shifts elsewhere.

Financing risk

Many clinical-stage biotechs depend on Equity issuance to extend their cash runway. The timing and terms of any such transaction are material risks for existing shareholders.

Trading Patterns and Liquidity

Beyond the headline +25.77% change, the trading pattern visible from the screener provides a useful lens on how Whitehawk Therapeutics, Inc. actually moved through the session. The combination of a 4.93 USD reference level, reported volume of 5.27M, and a relative volume reading of 39.27 is informative in itself. Each of these figures captures a different facet of the market's reaction: price reflects the marginal valuation, volume measures aggregate participation, and relative volume contextualises that participation against the stock's own history.

In a market cap band reported at 243.8M USD, sustained moves typically require either a meaningful change in the perceived fundamental story or a substantial shift in the composition of the stock's investor base. One-day spikes that are not anchored in confirmed catalysts can be informative about market psychology but provide limited evidence about durable value creation. Traders evaluating WHWK in the days that follow will want to watch whether the elevated volume profile is sustained, whether intraday ranges narrow, and whether bid-ask spreads tighten as the session's enthusiasm normalises.

Liquidity considerations also matter. When a stock's traded volume runs at multiples of its average, the order book can briefly look very different from its usual state. In particular, market depth — the size of resting orders at each price level — can appear larger than it really is during the spike and thinner than it really is once the rush fades. For WHWK, that means execution conditions encountered during the 13 May 2026 session may not be representative of typical days, and investors should plan position sizing and exit strategies accordingly.

How This Move Compares to Other Top Gainers

Placing WHWK's +25.77% move in context with other names on the 13 May 2026 Top Gaining US Stocks screener helps highlight what made the session distinctive. On the same day, leaderboard names ranged from deeply micro-cap issuers such as Dreamland Limited (TDIC) and Fitness Champs Holdings (FCHL) to larger small- and mid-caps like Ouster (OUST) and SELLAS Life Sciences (SLS). That breadth — both in sector and in market capitalisation — suggests the day's risk-on tone was broadly distributed rather than confined to a single theme.

Within that mixed cohort, WHWK sat alongside companies from healthcare, advanced Manufacturing, energy transition, and financial services. Although each of these names has its own operating story, their simultaneous appearance on the screener illustrates a pattern frequently observed in US markets: when small- and micro-cap appetite returns, capital tends to disperse across themes rather than concentrate in one. That dispersion can itself be a signal worth tracking, because it differentiates broad-based risk-on sessions from sentiment events focused on a single sector.

The relative-volume reading of 39.27 for WHWK should be read against the wide range observed in the day's gainers. Some names featured relative volumes in the high 20s, 30s, and even above 70, while others showed more moderate spikes in the 2–6 range. Where a particular stock sits in that distribution offers a clue about how unusual the day's activity was for that specific name — a more meaningful comparison than focusing solely on the headline percentage gain.

Investor Outlook

For WHWK, the 13 May 2026 session is dominated by the volume spike. Whether the move marks the start of a sustained shift in the stock's trading profile or a single-day burst of attention will depend on whether the underlying conditions persist.

Long-term investors will continue to focus on clinical milestones, Partnership announcements, and balance-sheet position. None of these can be assessed from the screener data alone, and any meaningful change in any of them can rapidly alter the Investment case.

Active traders may continue to monitor WHWK alongside other small-cap biotechs, watching for follow-through, exhaustion signals, and behaviour at key technical levels. Given the binary nature of clinical-stage outcomes, position sizing should reflect the wide range of potential outcomes.

Overall, the move highlights the way clinical-stage biotechs can experience extraordinary single-day volume spikes and underscores the importance of careful Fundamental Analysis in the segment.